A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US

Clinical trial NCT03597399 · COMPLETED

Trial details

NCT number: NCT03597399
Sponsor: Spark Therapeutics, Inc.
Status: COMPLETED
Study type: OBSERVATIONAL

Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy

Start date: 2019-01-10
Primary completion: 2025-06-30
Enrollment: 87

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.